Patients Make New Medicines Possible

Pieris Pharmaceuticals is currently enrolling patients in respiratory and immuno-oncology clinical trials. New treatments are made possible by volunteers who participate in clinical trials and we highly encourage and welcome your participation.

A Phase 1 Healthy Volunteer Trial of PRS-220 for IPF

Our Phase 1 study is designed to investigate the safety, tolerability, and pharmacokinetics of PRS-220, a drug candidate being developed to treat IPF.

About Phase 1 Healthy Volunteer Trial of PRS-220

Immuno-Oncology Trials

A Phase 1 Study of PRS-344/S095012 to Treat Advanced Solid Tumors

This global, open-label phase 1/2 dose escalation study is evaluating the safety, tolerability, potential optimal dosage, and potential anti-tumor activity of PRS-344/S095012 in patients with advanced solid tumors whose cancer progressed on standard-of-care treatment.